Neuronetics STIM 深 沪
等待开盘 02-20 09:30:00 美东时间
1.34
-0.040
-2.90%
华盛通- 最 高1.40
- 今 开1.39
- 成交量 182.55万股
- 最 低 1.30
- 昨 收 1.38
- 总市值 9177.11万
- 52周最高 5.92
- 市盈率 静 --
- 换手率 2.67%
- 52周最低 1.25
- 委 比 -24.70%
- 总股本 6848.59万
- 历史最高 39.39
- 量 比 0.29
- 振 幅 7.25%
- 历史最低 0.52
- 每 手 1
- 风险率 1.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 英伟达液冷供应商Vertiv跳空大涨超24%！Q4订单量大增252%；博格华纳涨超22%
英伟达液冷供应商Vertiv跳空大涨超24%！Q4订单量大增252%；博格华纳涨超22%，获得电驱动差速器合同，Q4营收超预期>>
02-12 15:26
Why Teradata Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of Teradata Corp (NYSE:TDC) rose sharply in pre-market trading after the...
02-11 17:25
Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On?
Neuronetics shares jumped 41% in after-hours trading following strong preliminary fourth-quarter 2025 revenue results.
02-11 13:20
Neuronetics Reports 86% Revenue Growth in Fourth Quarter 2025
Neuronetics Reports 86% Revenue Growth in Fourth Quarter 2025 Neuronetics Inc. announced selected preliminary unaudited financial results for the fourth quarter and full year 2025. The company reported fourth quarter 2025 revenue of $41.8 million, representing an 86% increase year-over-year on an as
02-11 05:37
Neuronetics shares are trading higher after the company reported preliminary Q4 and FY25 financial results.
Neuronetics shares are trading higher after the company reported preliminary Q4...
02-11 05:36
Neuronetics Reports Q4 Preliminary Revenue $41.8M, FY25 Revenue $149.2M
Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients
02-11 05:36
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
Neuronetics reported strong financial results for Q4 and full-year 2025, with revenue growth of 86% YoY (as reported) and 23% YoY (adjusted pro forma). Full-year revenue reached $149.2 million, up 99% YoY (as reported) and 15% YoY (adjusted pro forma). The company achieved positive operating cash flow of $0.9 million in Q4 and ended the year with $34.1 million in total cash. Keith Sullivan, CEO, highlighted strong commercial execution and demand ...
02-10 21:34
Neuronetics Amends Credit Agreement With Perceptive Credit Holdings
Neuronetics Amends Credit Agreement With Perceptive Credit Holdings Neuronetics Inc. has announced an amendment to its existing credit agreement with Perceptive Credit Holdings IV, LP and other lenders. The amendment, effective January 15, 2026, modifies the requirements for subsidiaries joining as
01-22 20:31
Neuronetics Grants Retention-Focused Incentive Awards to Executives
The latest update is out from Neuronetics ( ($STIM) ). On December 30, 2025, Ne...
01-07 06:30
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
Neuronetics, Inc. announced that its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The company, a leader in neurohealth therapies, provides non-drug treatments for mental health conditions, including NeuroStar Advanced Therapy, which has delivered over 7.4 million treatments for major depressive disorder (MDD). The therapy is FDA-cleared and supported by extensive c...
2025-11-20 13:30
